Sigilon Therapeutics, Inc. announced the appointment of Sarah Yuan, Ph.D., as Chief Technical Operations Officer, effective March 7th, 2022. Dr. Yuan brings more than 20 years of experience in process development, manufacturing sciences and CMC strategies from a broad range of leading biopharmaceutical companies. Prior to joining Sigilon Therapeutics, Dr. Yuan served as Vice President of Process and Analytical Development at 2seventy bio, the oncology spinoff of bluebird bio.